S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.09%) 40 140 points
Nasdaq Futures
(-0.05%) 18 465 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.17%) $0.928
USD/NOK
(0.20%) $10.86
USD/GBP
(0.00%) $0.792
USD/RUB
(0.03%) $92.61

Realtime updates for Prescient Therapeutics [PTX.AX]

Exchange: ASX Industry: Pharmaceuticals, Biotechnology & Life Sciences
Last Updated28 Mar 2024 @ 01:10

10.00% $ 0.0550

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 01:10):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302
Profile picture for Prescient Therapeutics Ltd

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations...

Stats
Today's Volume 706 563
Average Volume 1.05M
Market Cap 44.29M
EPS $0 ( 2024-02-21 )
Last Dividend $7.15 ( 1993-10-21 )
Next Dividend $0 ( N/A )
P/E -5.50
ATR14 $0 (0.00%)

Prescient Therapeutics Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Prescient Therapeutics Financials

Annual 2023
Revenue: $2.43M
Gross Profit: $2.43M (99.91 %)
EPS: $-0.00960
Q2 2023
Revenue: $0
Gross Profit: $0 (0.00 %)
EPS: $-0.00450
Q4 2023
Revenue: $1.17M
Gross Profit: $1.17M (100.00 %)
EPS: $-0.00540
Q3 2022
Revenue: $586 767
Gross Profit: $586 767 (100.00 %)
EPS: $-0.00270

Financial Reports:

No articles found.

Prescient Therapeutics Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Prescient Therapeutics Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future
Information
First Dividend $5.72 1990-10-25
Last Dividend $7.15 1993-10-21
Next Dividend $0 N/A
Payout Date 1993-12-31
Next Payout Date N/A
# dividends 2 --
Total Paid Out $12.87 --
Avg. Dividend % Per Year 0.00% --
Score 0.22 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
(2026-10-05)
$0 Estimate 0.00 %
Dividend Stability
0.00 Very Bad
Dividend Score
0.22
Pay Frequency
Sporadic
Yearly Payout
Year Amount Yield

Warning: Undefined variable $stockPricesArray in /home/getagraph/public_html/stock.php on line 1111

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for ASX

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
ORA.AX Ex Dividend Knight 2023-09-01 Semi-Annually 0 0.00%
ALD.AX Ex Dividend Knight 2023-09-01 Semi-Annually 0 0.00%
GNC.AX Ex Dividend Knight 2023-07-05 Annually 0 0.00%
QRI.AX Ex Dividend Knight 2023-09-05 Monthly 0 0.00%
BKL.AX Ex Dividend Knight 2023-07-25 Annually 0 0.00%
JMS.AX Ex Dividend Knight 2023-05-04 Semi-Annually 0 0.00%
SKC.AX Ex Dividend Junior 2023-09-07 Annually 0 0.00%
CLX.AX Ex Dividend Knight 2023-09-14 Annually 0 0.00%
MPL.AX Ex Dividend Knight 2023-09-13 Semi-Annually 0 0.00%
VCX.AX Ex Dividend Junior 2023-08-21 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM-6.601.500-10.00-10.00[0 - 0.5]
returnOnAssetsTTM-0.3131.200-10.00-10.00[0 - 0.3]
returnOnEquityTTM-0.3181.500-4.65-6.97[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM10.260.80010.008.00[1 - 3]
quickRatioTTM9.960.80010.008.00[0.8 - 2.5]
cashRatioTTM3.081.50010.0010.00[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM01.000-1.111-1.111[3 - 30]
operatingCashFlowPerShareTTM-0.009522.00-0.00317-0.00635[0 - 30]
freeCashFlowPerShareTTM-0.009522.00-0.00476-0.00952[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM1.0001.00010.0010.00[0.2 - 0.8]
operatingProfitMarginTTM-9.831.000-10.00-10.00[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM0.04740.800-3.02-2.41[0.5 - 2]
Total Score-0.962

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-5.621.000-0.6680[1 - 100]
returnOnEquityTTM-0.3182.50-2.99-6.97[0.1 - 1.5]
freeCashFlowPerShareTTM-0.009522.00-0.00317-0.00952[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-0.009522.00-0.00317-0.00635[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-1.9471.500-10.000[0.5 - 2]
operatingCashFlowSalesRatioTTM-6.531.000-10.000[0.1 - 0.5]
Total Score-2.81

Prescient Therapeutics

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators